Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01273922 · ClinicalTrials.gov registry record · Phase 1
Safety and Immunogenicity Study of a Recombinant Protein Vaccine (NDV-3) Against S.Aureus and Candida
A Phase 1 study, sponsored by NovaDigm Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT01273922 is a Phase 1 study that has completed, run by NovaDigm Therapeutics. The registered enrollment target is 40 participants.
The verdict
NCT01273922, a Phase 1 study, has completed, sponsored by NovaDigm Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
This randomized, double-blind, placebo-controlled study is a first-in-human Phase 1 study using two dose levels of an investigational vaccine directed against S. aureus and Candida. The study is designed to evaluate the safety, tolerability and immunogenicity of the investigational vaccine, NDV-3
Interventions
- BIOLOGICAL NDV-3 investigational vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2011-01 |
| Est. Completion | 2011-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01273922
The ClinicalTrials.gov registry entry for NCT01273922 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NovaDigm Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NDV-3 investigational vaccine is the first listed.
NCT01273922 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01273922 about?
NCT01273922 is a clinical study titled "Safety and Immunogenicity Study of a Recombinant Protein Vaccine (NDV-3) Against S.Aureus and Candida". This randomized, double-blind, placebo-controlled study is a first-in-human Phase 1 study using two dose levels of an investigational vaccine directed against S. aureus and Candida. The study is designed to evaluate the safety, tolerability and immunogenicity of the investigational vaccine, NDV-3
What is the current status of trial NCT01273922?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2011-01. Estimated completion is 2011-12.
What interventions are being tested in trial NCT01273922?
The interventions under investigation include: NDV-3 investigational vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01273922?
This trial is sponsored by NovaDigm Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.